Venetoclax safe, shows promise in patients with acute myelogenous leukemia

Posted by on August 12, 2016 11:36 am
Tags:
Categories: health

Patients whose acute myelogenous leukemia (AML) had relapsed or was resistant to chemotherapy and those who were deemed unable to tolerate chemotherapy experienced responses to the selective BCL-2 inhibitor venetoclax (Venclexta), with complete remissions in some, according to phase II clinical trial data.

Leave a Reply

Your email address will not be published. Required fields are marked *